yperinsulinemic-Euglycemic Clamp Strengthens the I... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

yperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasi

Full text
Author(s):
Delai, Ariane [1] ; Gomes, Patricia M. [1] ; Foss-Freitas, Maria Cristina [1, 2, 3] ; Elias Jr, Jorge ; Antonini, Sonir R. [4] ; Castro, Margaret [1] ; Moreira, Ayrton C. [1] ; Mermejo, Livia M. [1]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Internal Med, BR-14049900 Ribeirao Preto, SP - Brazil
[2] Univ Michigan, Caswell Diabet Inst, Ann Arbor, MI 48109 - USA
[3] Univ Michigan, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 - USA
[4] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto - Brazil
Total Affiliations: 4
Document type: Journal article
Source: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM; v. 107, n. 3, p. E1106-E1116, FEB 17 2022.
Web of Science Citations: 0
Abstract

Objective Insulin sensitivity evaluation by hyperinsulinemic-euglycemic clamp in nonclassical congenital adrenal hyperplasia (NC-CAH) due to 21-hydroxilase deficiency. Design and Setting Cross-sectional study at university hospital outpatient clinics. Patients and Methods NC-CAH patients (25 females, 6 males; 24 +/- 10 years) subdivided into C/NC (compound heterozygous for 1 classical and 1 nonclassical allele) and NC/NC (2 nonclassical alleles) genotypes were compared to controls. Results At diagnosis, C/NC patients presented higher basal and adrenocorticotropin-stimulated 17-hydroxyprogesterone and androstenedione levels than NC/NC genotype. Patients and controls presented similar weight, body mass index, abdominal circumference, and total fat body mass. NC-CAH patients showed higher waist-to-hip ratio, lower adiponectin and lower high-density lipoprotein cholesterol levels with no changes in fasting plasma glucose, glycated hemoglobin, homeostatic model assessment for insulin resistance, leptin, interleukin 6, tumor necrosis factor alpha, C-reactive protein, and carotid-intima-media thickness. All patients had used glucocorticoid (mean time of 73 months). Among the 22 patients with successful clamp, 13 were still receiving glucocorticoid-3 patients using cortisone acetate, 9 dexamethasone, and 1 prednisone (hydrocortisone equivalent dose of 5.5mg/m(2)/day), while 9 patients were off glucocorticoid but had previously used (hydrocortisone equivalent dose of 5.9mg/m(2)/day). The NC-CAH patients presented lower M-ffm than controls (31 +/- 20 vs 55 +/- 23 mu mol/min(-1)/kg(-1), P = 0.002). The M-ffm values were inversely correlated with the duration of glucocorticoid treatment (r = -0.44, P = 0.04). There was association of insulin resistance and glucocorticoid type but not with androgen levels. Conclusion Using the gold standard method, the hyperinsulinemic-euglycemic clamp, insulin resistance was present in NC-CAH patients and related to prolonged use and long-acting glucocorticoid treatment. Glucocorticoid replacement and cardiometabolic risks should be monitored regularly in NC-CAH. (AU)

FAPESP's process: 18/10789-4 - Cardio-metabolic risk factors in patients with non classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Grantee:Lívia Mara Mermejo
Support Opportunities: Regular Research Grants